NeoGenomics achieved a key legal victory as the Middle District of North Carolina invalidated Natera’s patents underpinning its Signatera assay, enabling NeoGenomics to resume commercialization of its Radar MRD platform, now rebranded as Radar ST for solid tumors. Following a permanent injunction imposed by Natera last year, this ruling lifts marketing restrictions and reduces legal expenditures. NeoGenomics is pursuing Medicare coverage for multiple cancer indications, aiming to capitalize on the broad $3 billion breast cancer market.